Comerica Bank Sells 4,028 Shares of United Therapeutics Corporation $UTHR

Comerica Bank decreased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 2.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 157,952 shares of the biotechnology company’s stock after selling 4,028 shares during the period. Comerica Bank owned 0.37% of United Therapeutics worth $66,215,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of United Therapeutics during the second quarter worth $136,453,000. Invesco Ltd. boosted its position in shares of United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares in the last quarter. AQR Capital Management LLC grew its stake in United Therapeutics by 40.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after buying an additional 364,713 shares during the last quarter. Balyasny Asset Management L.P. grew its stake in United Therapeutics by 863.9% during the 2nd quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock worth $43,886,000 after buying an additional 136,883 shares during the last quarter. Finally, Sofinnova Investments Inc. acquired a new position in United Therapeutics during the 2nd quarter valued at about $34,055,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wells Fargo & Company raised their price target on United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a report on Thursday, February 26th. Royal Bank Of Canada upped their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Cantor Fitzgerald increased their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday. Oppenheimer lifted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Finally, HC Wainwright boosted their target price on shares of United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $548.09.

United Therapeutics Stock Performance

Shares of UTHR opened at $536.12 on Friday. The stock has a 50-day moving average of $486.67 and a two-hundred day moving average of $460.13. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $548.12. The stock has a market cap of $23.50 billion, a P/E ratio of 19.22, a P/E/G ratio of 1.92 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the previous year, the business earned $6.19 EPS. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. Analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In related news, Director Ray Kurzweil sold 4,910 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $489.02, for a total transaction of $2,401,088.20. Following the completion of the transaction, the director owned 12,670 shares of the company’s stock, valued at $6,195,883.40. This trade represents a 27.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Christopher Causey sold 1,000 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $520.00, for a total transaction of $520,000.00. Following the transaction, the director owned 4,190 shares of the company’s stock, valued at $2,178,800. This represents a 19.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 338,947 shares of company stock valued at $165,516,573 over the last quarter. Company insiders own 10.30% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.